Healthcare CDMO Companies and Organizational Growth Plans

Latest Updates of Key Players in the Healthcare CDMO Market

Lonza Group AG

Headquarters: Switzerland
Latest update: In April 2025, Lonza announced that its new simplified and streamlined operating model is effective. Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy.

Thermo Fisher Scientific Inc

Headquarters: United States
Latest update: In 2025, Thermo Fisher Scientific (TMO) will have aggressively strengthened its position as a top-tier global Healthcare Contract Development and Manufacturing Organization (CDMO).

Catalent, Inc.

Headquarters: United States
Latest update: Catalent delivers end-to-end pharma solutions as a trusted CDMO, advancing drug development and manufacturing worldwide.

WuXi AppTec

Headquarters: China
Latest update: WuXi AppTec has demonstrated robust financial resilience and continued, rapid expansion as a Contract Research, Development, and Manufacturing Organization (CRDMO).

Samsung Biologics

Headquarters: South Korea
Latest update: Samsung Biologics provides seamless development and manufacturing services from cell line development to final aseptic fill/finish.

Siegfried Holding AG

Headquarters: Switzerland
Latest update: Siegfried signed binding agreements to acquire three drug substance sites in the US and Australia.

Value Chain Analysis: Healthcare CDMO Market

R&D:

• Major R&D processes in a CDMO include drug discovery support, pre-formulation and formulation development, process development and optimization, diagnostic method development, stability research, and clinical trial material (CTM) manufacturing.
• Key Players: Samsung Biologics Co., Ltd. and WuXi Biologics Co., Ltd.

Manufacturing Processes:

• Manufacturing processes for healthcare CDMO include manufacturing the active pharmaceutical ingredient (API) and then altering it into the final drug product.
• Key Players: Thermo Fisher Scientific Inc. and Catalent, Inc.

Patient Services:

• Healthcare CDMO, patient services involve specialized health plans intended to bridge the gap between drug manufacturing and the end-user's healthcare results. 
• Key Players: Thermo Fisher Scientific Inc. and Lonza Group AG

Market Growth

The global healthcare CDMO market size was estimated at USD 306.3 billion in 2025 and is predicted to increase from USD 337.3 billion in 2026 to approximately USD 803.17 billion by 2035, expanding at a CAGR of 10.12% from 2026 to 2035.

Recent Developments in the Healthcare CDMO Market

• In December 2025, Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization, announced that it had signed a CDMO master services agreement with a new large global pharmaceutical customer.
• In September 2025, Evonik, a worldwide specialty chemicals company, and Ethris, a healthcare-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, entered into a strategic partnership to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery.
• In June 2025, SAVA Healthcare Limited, a leading contract development and manufacturing organization (CDMO) in the Indian pharmaceutical sector, announced that it had received its first drug approval from the Drug Controller General of India (DCGI) for a combination nasal spray indicated for the treatment of allergic rhinitis with nasal congestion.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com